UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy

Biomolecules (Basel, Switzerland), 2023-06, Vol.13 (6), p.984

2023

Volltextzugriff (PDF)

Effect of autophagy on multiple myeloma cell viability

Molecular cancer therapeutics, 2009-07, Vol.8 (7), p.1974-1984

2009

Volltextzugriff (PDF)

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

Blood, 2010-11, Vol.116 (22), p.4560-4568

2010

Volltextzugriff (PDF)

The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance

The Journal of biological chemistry, 2012-06, Vol.287 (26), p.21796-21805

2012

Volltextzugriff (PDF)

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade

Molecular cancer therapeutics, 2005-10, Vol.4 (10), p.1533-1540

2005

Volltextzugriff (PDF)

Cyclin D1 and c-myc Internal Ribosome Entry Site (IRES)-dependent Translation Is Regulated by AKT Activity and Enhanced by Rapamycin through a p38 MAPK- and ERK-dependent Pathway

The Journal of biological chemistry, 2005-03, Vol.280 (12), p.10964-10973

2005

Volltextzugriff (PDF)

AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression

The Journal of biological chemistry, 2004-01, Vol.279 (4), p.2737-2746

2004

Volltextzugriff (PDF)

SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism

Molecular cancer research, 2016-04, Vol.14 (4), p.397-407

2016

Volltextzugriff (PDF)

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

Blood, 2004-12, Vol.104 (13), p.4181-4187

2004

Volltextzugriff (PDF)

MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses

PloS one, 2014-04, Vol.9 (4), p.e94011-e94011

2014

Volltextzugriff (PDF)

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779

Cancer research (Chicago, Ill.), 2002-09, Vol.62 (17), p.5027-5034

2002

Volltextzugriff (PDF)

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (4), p.2305-2313

2006

Volltextzugriff (PDF)

Mammalian Target of Rapamycin Inhibitors Induce Tumor Cell Apoptosis In Vivo Primarily by Inhibiting VEGF Expression and Angiogenesis

Journal of Oncology, 2013-01, Vol.2013 (2013), p.255-266

2013

Volltextzugriff (PDF)

IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1

Cancer research (Chicago, Ill.), 2008-12, Vol.68 (24), p.10215-10222

2008

Volltextzugriff (PDF)

Targeting aurora kinases as therapy in multiple myeloma

Blood, 2007-05, Vol.109 (9), p.3915-3921

2007

Volltextzugriff (PDF)

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses

Oncogene, 2002-02, Vol.21 (9), p.1391-1400

2002

Volltextzugriff (PDF)

Downstream effectors of oncogenic ras in multiple myeloma cells

Blood, 2003-04, Vol.101 (8), p.3126-3135

2003

Volltextzugriff (PDF)

The AKT kinase is activated in multiple myeloma tumor cells

Blood, 2001-11, Vol.98 (9), p.2853-2855

2001

Volltextzugriff (PDF)

Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation

The Journal of biological chemistry, 2022-04, Vol.298 (4), p.101750-101750, Article 101750

2022

Volltextzugriff (PDF)

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance

Blood, 2006-06, Vol.107 (11), p.4484-4490

2006

Volltextzugriff (PDF)

Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

Oncogene, 2004-04, Vol.23 (19), p.3368-3375

2004

Volltextzugriff (PDF)

IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells

The Journal of biological chemistry, 2011-01, Vol.286 (1), p.67-78

2011

Volltextzugriff (PDF)

Acetazolamide affects breathing differently in ICR and C57 mice

Respiratory physiology & neurobiology, 2006-06, Vol.152 (2), p.119-127

2006

Volltextzugriff (PDF)

Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma

Molecular cancer therapeutics, 2022-04, Vol.21 (4), p.502-510

2022

Volltextzugriff (PDF)

A Deptor Inhibitor Induces Its Degradation with Resulting Anti-Myeloma Cytotoxicity in Vitro and In Vivo

Blood, 2019-11, Vol.134 (Supplement_1), p.1821-1821

2019

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(125)

Publikationsform

Sprache

Englisch
(135)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy

Effect of autophagy on multiple myeloma cell viability

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade

Cyclin D1 and c-myc Internal Ribosome Entry Site (IRES)-dependent Translation Is Regulated by AKT Activity and Enhanced by Rapamycin through a p38 MAPK- and ERK-dependent Pathway

AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression

SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses

Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

Mammalian Target of Rapamycin Inhibitors Induce Tumor Cell Apoptosis In Vivo Primarily by Inhibiting VEGF Expression and Angiogenesis

IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1

Targeting aurora kinases as therapy in multiple myeloma

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses

Downstream effectors of oncogenic ras in multiple myeloma cells

The AKT kinase is activated in multiple myeloma tumor cells

Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance

Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells

Acetazolamide affects breathing differently in ICR and C57 mice

Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma

A Deptor Inhibitor Induces Its Degradation with Resulting Anti-Myeloma Cytotoxicity in Vitro and In Vivo

Suchergebnisse filtern